Postprandial blood sugar and insulin reduction
A human RCT of Eriomin® (200 mg/day) demonstrated significant reductions in postprandial blood glucose and insulin response after 12 weeks — with improvements in both fasting glucose and the 2-hour glucose excursion during oral glucose tolerance testing. Mechanisms include alpha-glucosidase inhibition and improved insulin receptor sensitivity.
Uric acid reduction
Eriocitrin significantly reduces serum uric acid levels through xanthine oxidase inhibition — the same mechanism as the gout medication allopurinol, but at a natural supplement dose. Studies show meaningful reductions in hyperuricemia with regular Eriomin® supplementation, with potential applications in gout prevention and metabolic syndrome management.
Antioxidant and anti-inflammatory activity
Eriocitrin and its metabolite eriodictyol are potent free radical scavengers with ORAC values among the highest of citrus flavonoids. Clinical studies show reductions in oxidized LDL, CRP, and inflammatory markers with regular eriocitrin supplementation — contributing to cardiovascular and metabolic protective effects.
Cardiovascular protection
Eriocitrin improves endothelial function, reduces blood pressure, and decreases platelet aggregation through mechanisms including nitric oxide enhancement and eicosanoid modulation. These cardiovascular protective effects position Eriomin® alongside other citrus flavonoids (hesperidin, naringenin) in the cardiovascular category.
Alpha-glucosidase and xanthine oxidase dual inhibition
Eriocitrin inhibits intestinal alpha-glucosidase (slowing carbohydrate digestion and glucose absorption) and xanthine oxidase (the enzyme producing uric acid from purines). This dual enzyme inhibition explains why eriocitrin simultaneously reduces postprandial blood glucose and serum uric acid — two key metabolic syndrome markers — through direct enzyme interaction.
PPAR-α activation and lipid metabolism
Eriodictyol (the aglycone of eriocitrin) activates PPAR-α transcription factor, stimulating fatty acid oxidation, reducing triglyceride synthesis, and improving overall lipid metabolism. This PPAR-α agonism contributes to the lipid-lowering and insulin-sensitizing effects of eriocitrin supplementation.
NF-κB inhibition and oxidative stress reduction
Eriocitrin inhibits NF-κB activation and reduces downstream inflammatory cytokine production. The antioxidant mechanism involves both direct free radical scavenging and Nrf2 pathway activation, providing complementary anti-inflammatory and antioxidant protection in metabolic tissues.
Randomized, double-blind, placebo-controlled trial of Eriomin® (200 mg/day) vs. placebo in 60 pre-diabetic adults for 12 weeks.
60 pre-diabetic adults (impaired fasting glucose). 12-week intervention.
Eriomin® significantly reduced fasting blood glucose (-8.7%), postprandial glucose AUC, insulin resistance (HOMA-IR), and uric acid levels vs. placebo. CRP and inflammatory markers also reduced. No adverse effects. First RCT establishing Eriomin® as a metabolic health ingredient.
Clinical study examining eriocitrin supplementation effects on serum uric acid and xanthine oxidase activity in adults with hyperuricemia.
Adults with elevated serum uric acid. 8-week supplementation.
Eriocitrin significantly reduced serum uric acid levels and inhibited xanthine oxidase activity. Reductions comparable to low-dose allopurinol in mild hyperuricemia. Well-tolerated with no adverse effects.